The National Health Commission has announced two key tasks for clinical laboratories. On March 17, the Commission's Medical Administration Bureau issued a notice outlining the 2026 National Medical Quality and Safety Improvement Goals, which define two primary focuses for clinical labs. The first is to increase the mutual recognition rate of inspection and test results among medical institutions, listed as one of the ten major goals. Ten core strategies were proposed, covering the establishment of a mutual recognition system, standardized equipment management, enhanced quality control, improved IT infrastructure, setting up dedicated inspection clinics, better doctor-patient communication, and creating monitoring and evaluation mechanisms. The second key task is to boost the participation rate in external quality assessment for clinical laboratory tests, designated as a core quality control objective for the clinical laboratory specialty. Four core strategies were provided, including establishing coordination mechanisms, strengthening training, improving monitoring and feedback systems, and utilizing management tools for continuous improvement. Additionally, quality control goals for several other specialties, including pediatrics and infectious diseases, also involve clinical laboratories.

Three government departments have jointly issued a document, marking the comprehensive entry of the IVD industry into the UDI era. On March 13, the National Medical Products Administration and two other departments jointly released Announcement No. 21, clarifying the implementation plan for the Unique Device Identification system for medical devices, with the IVD sector being a core focus. UDI serves as a "digital ID card" for medical devices. China's policy rollout has been gradual, starting with pilot programs for some high-risk Class III IVD products, then moving towards unified supervision and inclusion as a compliance requirement in multiple provinces, with clear responsibilities for market entities set for 2025. Announcement No. 21 breaks away from the "phased pilot" approach, achieving "comprehensive coverage" of UDI for all IVD categories and coordinating efforts across the three departments to integrate the entire supply chain. It mandates the full implementation of UDI for all IVD products subject to registration management, with impacts spanning the entire chain. For regulators, it enables precise traceability and raises compliance thresholds. For manufacturers, there is short-term pressure, but long-term benefits for high-quality development. For distribution and clinical use, it closes the traceability loop. For healthcare payers, it facilitates precise cost control and standardizes fund usage. The announcement urges the IVD industry to accelerate implementation, requiring companies to complete production line modifications to ensure compliance and drive digital transformation. The advancement of UDI in the IVD sector reflects both regulatory and industrial upgrading, presenting short-term challenges but long-term developmental advantages, and companies are advised to proactively adapt to the policy.

Roche is collaborating with NVIDIA to build an AI factory. On March 16, Roche announced the expansion of its global AI infrastructure by deploying a large-scale AI factory powered by NVIDIA's latest generation of accelerated computing and full-stack AI technology. This infrastructure, already deployed with 2,176 high-performance GPUs in the United States and Europe, spans the entire value chain and aims to accelerate the development of diagnostic solutions and therapeutics.

Vazyme and Zhongke Puruisheng have entered into a strategic partnership. On March 17, Nanjing Vazyme Biotech Co., Ltd. signed a strategic cooperation agreement with Hefei Zhongke Puruisheng Biopharmaceutical Technology Co., Ltd. This collaboration marks a new stage of synergy between the two companies in the fields of life sciences and biopharmaceuticals. Moving forward, they will continue to deepen their cooperation, explore more application scenarios, and work together to create a model for industry-academia-research-application collaborative innovation, contributing more expertise and strength to serving human health.

JD Health and Cofoe Medical have further upgraded their strategic partnership. On March 16, JD Health and Cofoe Medical announced a comprehensive deepening of their strategic cooperation, targeting a 150% year-on-year sales increase. Centered on "AI + Medical Devices," the partnership aims to promote the intelligent upgrade of seven major product categories and build a new ecosystem for intelligent health management across the entire life cycle. Zhang Zhiming, Vice Chairman of Cofoe Medical, expressed anticipation for integrating the company's professional expertise with JD Health's digital and intelligent capabilities to define new standards for home-use medical devices in the AI era. A representative from JD Health stated they would open their core capabilities to jointly develop intelligent health products, reaching hundreds of millions of households. The collaboration covers the entire supply chain. In the respiratory health sector, Cofoe's new intelligent ventilator model C11 B25S will debut exclusively on JD.com on March 21; previously co-developed products have achieved significant sales success. Targeting the elderly population, plans are underway to develop new products like AI-powered hearing aids, providing one-stop health solutions. The cooperation also extends to areas such as health monitoring, protective testing, medical aesthetics, and traditional Chinese medicine healthcare, with multiple new products scheduled for exclusive launches.

Leadership change is imminent at multi-cancer early screening leader GRAIL. On March 12, 2026, GRAIL announced that its 66-year-old CEO, Bob Ragusa, will retire and step down on June 1. Bob joined GRAIL in 2021, having previously served as COO at Illumina and as a director at Twist Biosciences. His retirement at this time is easily associated with taking responsibility for the stock price plunge following the clinical setback in the NHS study. GRAIL's board has appointed Dr. Josh Ofman, the company's President, to succeed as CEO, with Ofman joining the board immediately. Notably, Josh served as CMO from 2020 to 2021, and the NHS-Galleri clinical study was launched in September 2021, making it likely he approved the initial study design. GRAIL has experienced frequent CEO changes, with six CEOs over ten years, including four changes between 2016 and 2019. At the time of writing, GRAIL's stock price had declined by 4.8%.

Desight Biotechnology has passed the Hong Kong Stock Exchange hearing. Hangzhou Desight Biotechnology Co., Ltd. recently passed the listing hearing of the Hong Kong Stock Exchange, with Huatai International as the sponsor, positioning it to become the "first stock in the medical imaging large model" sector. Founded in 2016, the company offers diverse products. Its core product, AI AutoVision®, is a chromosome karyotype analysis-assisted diagnosis software that has completed clinical trials. It submitted an application for Class III medical device registration in May 2025 and has been recognized as an "Innovative Class III Medical Device." It demonstrates excellent detection performance and significantly improved analysis efficiency. Desight Biotechnology holds the leading market share in the chromosome karyotype analysis field, with its technical advantage stemming from its self-developed iMedImage® medical imaging foundational model. Revenue surged in the first three quarters of 2025, and the company has received investment from multiple institutions. Proceeds from the IPO will be used for R&D, commercialization, and other purposes, with its development closely aligned with national strategies.

ABclonal and Tengyun Biotech have reached a strategic cooperation agreement. On the afternoon of March 11, Wuhan ABclonal Biotechnology Co., Ltd. and Shanghai Tengyun Biotech Co., Ltd. formally signed a strategic cooperation agreement. Leveraging their respective core technological strengths and market resources in the single-cell sequencing field, the two parties will engage in comprehensive, in-depth collaboration centered on ABclonal's proprietary ABcellar® platform. This cooperation will span product sales, technical collaboration, and bioinformatics analysis, jointly promoting the intelligent upgrade of life science research tools and providing higher quality, more efficient single-cell solutions for researchers nationwide.

Puyi Biotechnology has completed a 150 million yuan Series B financing round. Recently, Puyi Biotechnology (Shaoxing) Co., Ltd. officially announced the completion of a 150 million RMB Series B financing round. This round was led by Zhejiang Galaxy Guoke Consumer Health Equity Investment Fund, with co-investment from Guoke Venture Capital, Bank of China Capital, Chang Development Group, and other institutions. Existing shareholders Wondfo Biotech and IDG Capital continued their investment. The funds will be primarily focused on four core areas: core technology iteration, large-scale production capacity construction, medical device registration, and global market expansion. The aim is to fully integrate and strengthen the positive "R&D-Production-Commercialization" business cycle, further solidifying the company's core competitiveness in the nanopore gene sequencing field.

Sansure Biotech makes another move, acquiring a Shenzhen POCT company for 93.39 million yuan. On March 15, 2026, in Changsha, Hunan, Sansure Biotech made its second strategic move within three days. Following a 90 million yuan investment in AI healthcare company Zheyuan Technology on March 12, the company announced plans to establish a joint venture with an affiliated party to acquire 100% equity of Huasi Wuwai Microbiological Technology for 93.3929 million yuan. Sansure Biotech will contribute 65.438 million yuan, with the affiliated fund investing 28.0449 million yuan. Huasi Wuwai is a national high-tech enterprise possessing core infrared fluorescence enhancement technology that can improve detection sensitivity and accuracy. This acquisition will help Sansure Biotech accelerate the expansion of its investment portfolio.

Tianwu Technology has completed an A+ funding round exceeding 200 million yuan. Recently, Tianwu Technology, an AI-driven full-stack protein R&D platform, completed an A+ funding round exceeding 200 million yuan. This round was jointly led by CNPC Kunlun Capital, existing shareholder Yonghua Investment, and Shanghai Future Industry Fund, with participation from SDIC Venture Capital, New Supply and Marketing Fund, Farmer Kai, Future Capital, and other institutions. Existing shareholders Qiming Venture Partners, GSR United Capital Runpu Healthcare Fund, and Herbal Capital continued their investment. Tianwu Technology is an AI-driven full-stack protein R&D platform company. By building a unique, ultra-large-scale protein sequence dataset/label library, it has created a universal large model for protein design, enabling precise design of functional proteins directly tailored to industrial needs.